China Pharma Holdings (CPHI) Share-based Compensation (2010 - 2026)

China Pharma Holdings' Share-based Compensation history runs 12 years deep, the most recent figure standing at $15.0 million for Q1 2026.

• Quarterly Share-based Compensation changed N/A year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (changed N/A YoY) and the FY2025 annual result came in at $17.9 million, up 384.88% from the prior year.
• Share-based Compensation was $15.0 million for Q1 2026 at China Pharma Holdings, down from $15.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $15.5 million in Q4 2025 and bottomed at -$491074.0 in Q2 2023.
• A 5-year average of $3.1 million and a median of $828726.0 in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 194014.07% — and 2023, when it tumbled 345.54%.
• China Pharma Holdings' Share-based Compensation stood at $1.0 million in 2022, then slumped by 140.7% to -$410000.0 in 2023, then surged by 668.29% to $2.3 million in 2024, then soared by 563.95% to $15.5 million in 2025, then declined by 3.08% to $15.0 million in 2026.
• Business Quant data shows CPHI's Share-based Compensation at $15.0 million in Q1 2026, $15.5 million in Q4 2025, and $2.3 million in Q4 2024.